The potential benefits of aldosterone antagonism in Type 2 diabetes mellitus. - Wikidata - awgldk - TriplyDB

The potential benefits of aldosterone antagonism in Type 2 diabetes mellitus.

The potential benefits of aldosterone antagonism in Type 2 diabetes mellitus.

http://www.wikidata.org/entity/Q35058628

about

Diabetes impairs the vascular effects of aldosterone mediated by G protein-coupled estrogen receptor activation Spironolactone reduces brachial pulse wave velocity and PIIINP levels in hypertensive diabetic patients.

P2860

Q35135440-39CFD547-0C55-4A7E-B6C9-56F8F2ABC9B2 Q35826976-FCB220F3-21B1-4CB8-B333-7FF568045BD0

P2860

The potential benefits of aldosterone antagonism in Type 2 diabetes mellitus.

http://www.wikidata.org/entity/Q35058628

description

2002 nî lūn-bûn

@nan

2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

The potential benefits of aldosterone antagonism in Type 2 diabetes mellitus.

@ast

The potential benefits of aldosterone antagonism in Type 2 diabetes mellitus.

@en

type

label

The potential benefits of aldosterone antagonism in Type 2 diabetes mellitus.

@ast

The potential benefits of aldosterone antagonism in Type 2 diabetes mellitus.

@en

prefLabel

The potential benefits of aldosterone antagonism in Type 2 diabetes mellitus.

@ast

The potential benefits of aldosterone antagonism in Type 2 diabetes mellitus.

@en

P1433

Q35058628-74E72AA2-3754-4377-A962-1DFADB5B5F27

P1476

Q35058628-5A10918B-5EE1-44CE-935A-A3321E04B4E1

P2093

Q35058628-0BC78429-462F-41D1-BFE8-05C873714DE9

Q35058628-E41FCE8B-4864-41F7-8059-828637797853

P2860

Q35058628-121916BF-3F0E-467D-ACE5-53B6DBA2FE9A

Q35058628-1B6FFC43-31C2-4F7B-BD6D-A3789C71C3B6

Q35058628-1BA12706-33CD-4E16-94F9-98F833FF5C67

Q35058628-206FE130-3574-4A44-867F-81340BE0CA35

Q35058628-2256B770-4C7B-428B-BB45-6C5EE5374552

Q35058628-2425FB3A-11E3-4404-A989-70291A065F36

Q35058628-2CF653E0-457D-4299-B03E-C9C822312556

Q35058628-2F81B11E-ED4F-4164-9FED-8FE3763F76C3

Q35058628-3AB1E400-DCD2-433B-81A7-8BD7A2149095

Q35058628-3DCE4705-68DD-4AA4-A540-F31D75D700B2

P304

Q35058628-C90F6645-5360-4F22-83B6-B9A6404B2D6E

P31

Q35058628-A310680F-AAAB-47A6-B467-D01869266087

P356

Q35058628-4FAFA1EC-A9B1-4800-B4E0-A4235EBAEAC0

P433

Q35058628-A7ECDB8C-5C01-4E34-BD7C-E490C0F491A9

P478

Q35058628-D4E68FE8-94C2-41DF-85C6-50A479E67A2A

P577

Q35058628-A3123E5A-8E74-4EE8-AE4C-2EB7F30852E0

P698

Q35058628-FD670635-DB68-447B-AD85-95C69E981F4A

P921

Q35058628-1960620A-0B09-42FF-8ACC-E04664F943BA

P356

14703203020030030301

P1433

Journal of the Renin-Angiotensin-Aldosterone System

P1476

The potential benefits of aldosterone antagonism in Type 2 diabetes mellitus.

@en

P2093

Allan Struthers

http://www.w3.org/2001/XMLSchema#string

Justine Davies

http://www.w3.org/2001/XMLSchema#string

P2860

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

Expression of mineralocorticoid and glucocorticoid receptor mRNA in the human hippocampus

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

Fortnightly review: Beneficial effects of potassium

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study

Aldosterone production is activated in failing ventricle in humans.

Mineralocorticoid receptor-mediated signaling regulates the ion gated sodium channel in vascular endothelial cells and requires an intact cytoskeleton.

Why does spironolactone improve mortality over and above an ACE inhibitor in chronic heart failure?

P304

150-155

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/14703203020030030301

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2002-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12563564

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes